For effective treatment of andro-genetic alopecia.
Follicum AB is a biotech company in the Coegin Pharma Group. Our drug candidate FOL005 is a peptide based drug candidate for both men and women who suffer from hairloss.
It is a great pleasure to present Coegin Pharma’s new portfolio company with the primary objective to develop an effective treatment with a novel and proprietary peptide based drug candidate for men and women who suffer from hair loss.
In addition, we are exploring an interesting opportunity to develop an effective treatment for patients suffering from chronic wounds. The new portfolio company takes its name from Follicum which was the company acquired by Coegin Pharma in 2021 and which brought forward the new peptide, FOL005, characterized the unique mechanism of action and developed an advanced and cosmetically attractive formulation
The market for treatment of androgenetic alopecia (hair loss) is substantial. In the US alone 60 million men and 35 million women are suffering from hair loss whereas only 2,7 million men and 2 million women are being treated. The current market for medical treatments is valued at more than 5 billion USD globally.
Finasteride and minoxidil are the dominant medical treatments, which have limited effect and only up to 40% of patients respond to treatment. In the last 30 years no new medical treatment has been introduced and the pipeline is based mainly on reformulation of these existing therapies.
Kristian Lykke Fick
Chief Executive Officer
& Board Member
Chairman of Board